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Introduction
Coenzyme Q10 is a naturally occurring substance and
essential element of the mitochondrial electron trans-
port chain. There has been a recent interest in the role
that mitochondria may play in migraine pathogenesis. If
indeed migraine results from mitochondrial dysfunction,
then coenzyme Q10 could be used as a successful
migraine preventive therapy. Abnormal mitochondrial
function translates into high intracellular penetration of
Ca(2+), excessive production of free radicals, and defi-
cient oxidative phosphorylation, which ultimately causes
energy failure in neurons and astrocytes, thus triggering
migraine mechanisms. The objective of this investigation
was to confirm the efficacy of coenzyme Q10 as a pre-
ventive treatment for migraine headaches.
Materials and methods
We selected from the Headache Center of the “Istituto
Clinico Città di Brescia” a population of 40 patients aged
between 18 and 65 years, suffering from migraine without
aura with a headache frequency between 3 to 6 crises/
month (4 to 12 days with headache/month), not assuming
other migraine preventive therapy. They were randomly
assigned to treatment with coenzyme Q10 300 mg
(20 patients) or 600 mg (20 patients) once a day for
3 months. Patients were evaluated for frequency, duration,
intensity of pain, response to trigger factors and response
to their habitual analgesic drug (data obtained from the
diary of headache delivered at first visit). The improve-
ment of the thermographic pattern was also evaluated.
Results
A reduction in frequency and intensity of more than
50% in 25 patients, 10 patients reported reduction of
more than 50% in the intensity but not in frequency
(<50%), 5 patients had no improvement of symptoms. In
all patients the complexity of the accompanying symp-
toms were less severe and they noted a reduction of the
response to trigger factors.
Discussion and conclusions
Coenzyme Q10 is an essential element of the mitochon-
drial electron transport chain and has been shown to
improve mitochondrial oxidative phosphorylation in
humans. Coenzyme Q10, which can be administered orally
with an excellent side-effect profile, appears to be a good
migraine preventive.
Written informed consent to publication was obtained
from the patient(s).
Published: 28 September 2015
doi:10.1186/1129-2377-16-S1-A186
Cite this article as: Dalla Volta et al.: P026. Pilot study on the use of
coenzyme Q10 in a group of patients with episodic migraine without
aura. The Journal of Headache and Pain 2015 16(Suppl 1):A186.
* Correspondence: centrocefalea@gmail.com
Brescia Headache Centre, Istituto Clinico Città di Brescia, Brescia, Italy
Dalla Volta et al. The Journal of Headache and Pain 2015, 16(Suppl 1):A186
http://www.thejournalofheadacheandpain.com/content/16/S1/A186
© 2015 Volta et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://
creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the
original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/
zero/1.0/) applies to the data made available in this article, unless otherwise stated.
